Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Research interest in the application of electroencephalogram (EEG) as a non-invasive diagnostic tool for the automated detection of neurodegenerative diseases is growing. 2 key findings →

Participants: 88 Evidence: moderate

AI-Based Severity Classification of Dementia Using Gait Analysis

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Sensors 2025-10-02

This study aims to explore the utility of artificial intelligence (AI) in classifying dementia severity based on gait analysis data and to examine how machine learning (ML) can address the limitations of conventional statistical approaches. 1 key finding →

Participants: 34 Evidence: low

Sleep disturbances as risk factors for neurodegeneration later in life

✓ Peer-reviewed alzhub usefulness score 44 out of 100. npj Dementia 2025-05-27

We found that sleep disorders were associated with risk of Alzheimer’s disease (AD), amyotrophic lateral sclerosis, dementia, Parkinson’s disease (PD), and vascular dementia in three national biobanks (hazard ratios from 1.3 (PD) to 5.11 (dementia)). 2 key findings →

Evidence: low

A review of type 2 diabetes mellitus and cognitive impairment

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Frontiers in Endocrinology 2025-08-04

The association between type 2 diabetes mellitus (T2DM) and cognitive impairment represents a critical public health concern, particularly against the backdrop of the rising global prevalence of diabetes and aging populations. 2 key findings →

Evidence: low

Monoallelic TYROBP deletion is a novel risk factor for Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Molecular Neurodegeneration 2025-04-28

Biallelic loss-of-function variants in TYROBP and TREM2 cause autosomal recessive presenile dementia with bone cysts known as Nasu-Hakola disease (NHD, alternatively polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, PLOSL). 3 key findings →

Evidence: low

Seasonal and daily variation in indoor light and temperature are associated with sleep disturbance in dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. SLEEP 2025-04-30

Mechanisms regulating human sleep and physiology have evolved in response to rhythmic variation in environmental variables driven by the Earth's rotation around its axis and the Sun. 1 key finding →

Participants: 26 Evidence: low

The prevalence of CF was 24.3%. Cerebrovascular disease (OR: 2.39, 95% CI: 1.44-3.97) and peripheral arterial disease (OR: 1.74, 95% CI: 1.03-2.95) were significant risk factors, while higher education (OR 0.85, 95% CI 0.76-0.94) and later diabetes onset (OR: 0.93, 95% CI: 0.88-0.98) were protective. 5 key findings →

Design: cross-sectional Evidence: low

In partial correlations adjusted for age, there was a significant positive association between the cardiovascular composite (r = .156, p = .016) and resistance score; higher cardiovascular composite was associated with greater than expected Aβ for age. 4 key findings →

Participants: 262 Evidence: low

The Role of Oxidative Stress and Inflammation in the Pathogenesis and Treatment of Vascular Dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Cells 2025-04-17

Vascular dementia (VaD) is a heterogeneous group of brain disorders caused by cerebrovascular pathologies and the second most common cause of dementia, accounting for over 20% of cases and posing an important global health concern. 5 key findings →

Evidence: low

Mutations in the TARDBP gene encoding TDP-43 protein are linked to loss of function in neurons and familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). 5 key findings →

Evidence: low

Early isolated functional disruptions in salience/visual networks were present in asymptomatic carriers, along with anterior cingulate gray matter reductions. 5 key findings →

Evidence: low

Forty bvFTD patients and 40 HC (56.25% female, mean age of 63.55 years) were involved. 5 key findings →

Participants: 36 Evidence: low

The majority of individuals at 50% risk of carrying a pathogenic variant causing frontotemporal dementia (FTD) chooses not to undergo presymptomatic genetic testing. 5 key findings →

Participants: 14 Evidence: low

These findings establish IF as a potent modulator of synaptic resilience in VaD, acting through coordinated preservation of synaptic structure, inhibition of inflammatory synapse loss, and metabolic reprogramming. 2 key findings →

Evidence: low

The association between plasma and MRI biomarkers in dementia with lewy bodies

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s Research & Therapy 2025-08-22

In DLB, plasma concentrations of GFAP and NfL were associated with MTA, GCA-F, and Fazekas scale; and the Aβ42/40 ratio was associated with PA and Fazekas. 5 key findings →

Participants: 92 Evidence: low

Dopamine transporter (DAT) imaging and electroencephalography (EEG) are recommended biomarkers for diagnosing dementia with Lewy bodies (DLB). 4 key findings →

Participants: 120 Evidence: low

A one‐point ALI increase was associated with MCI conversion odds by 15%. 1 key finding →

Participants: 385 Evidence: low

-values compared to gait features. Linear regression analysis indicated that turn dynamics had stronger correlations with executive function and working memory, suggesting a more pronounced relationship between cognitive performance and turn features than gait variables. 3 key findings →

Participants: 75 Evidence: low

The left inferior parietal lobule (IPL)_6_5 (rostroventral area 39) showed the best ability to discriminate between patients with AD and those with CN (AUC = 0.688). 5 key findings →

Participants: 662 Evidence: low

The CNN-BiLSTM-Attention model demonstrated relatively promising predictive performance (AUC: 0.7317), with moderately high sensitivity (0.6902) and a high negative predictive value (NPV) of 0.9414. 5 key findings →

Participants: 4,626 Evidence: low

These findings suggest that visual function plays a crucial role in the cognitive and functional abilities of patients with MCI. 2 key findings →

Design: cross-sectional Evidence: low

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed